These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12407514)

  • 1. Peptide-based cancer vaccines.
    Machiels JP; van Baren N; Marchand M
    Semin Oncol; 2002 Oct; 29(5):494-502. PubMed ID: 12407514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
    Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
    Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [General principles and first clinical trials of therapeutic vaccines against cancer].
    Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
    Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.
    Palermo B; Del Bello D; Sottini A; Serana F; Ghidini C; Gualtieri N; Ferraresi V; Catricalà C; Belardelli F; Proietti E; Natali PG; Imberti L; Nisticò P
    Cancer Res; 2010 Sep; 70(18):7084-92. PubMed ID: 20823160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma peptide vaccines: from preclinical background to clinical trials.
    Weber J
    Curr Oncol Rep; 2000 Jan; 2(1):38-47. PubMed ID: 11122823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination for melanoma.
    Thompson LW; Brinckerhoff L; Slingluff CL
    Curr Oncol Rep; 2000 Jul; 2(4):292-9. PubMed ID: 11122856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
    François V; Ottaviani S; Renkvist N; Stockis J; Schuler G; Thielemans K; Colau D; Marchand M; Boon T; Lucas S; van der Bruggen P
    Cancer Res; 2009 May; 69(10):4335-45. PubMed ID: 19435913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma cancer vaccines and anti-tumor T cell responses.
    Vujanovic L; Butterfield LH
    J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide vaccine trials for melanoma: preclinical background and clinical results.
    Talebi T; Weber JS
    Semin Cancer Biol; 2003 Dec; 13(6):431-8. PubMed ID: 15001162
    [No Abstract]   [Full Text] [Related]  

  • 13. Rational development of peptide vaccination in clinical oncology.
    Keiholz U; Scheibenbogen C; Theil E; Schadendorf D
    Onkologie; 2001 Apr; 24(2):174. PubMed ID: 11476074
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
    Parmiani G; Castelli C; Dalerba P; Mortarini R; Rivoltini L; Marincola FM; Anichini A
    J Natl Cancer Inst; 2002 Jun; 94(11):805-18. PubMed ID: 12048268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
    Coulie PG; Karanikas V; Lurquin C; Colau D; Connerotte T; Hanagiri T; Van Pel A; Lucas S; Godelaine D; Lonchay C; Marchand M; Van Baren N; Boon T
    Immunol Rev; 2002 Oct; 188():33-42. PubMed ID: 12445279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-based vaccines for cancer therapy.
    Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
    Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.
    Engelhard VH; Bullock TN; Colella TA; Sheasley SL; Mullins DW
    Immunol Rev; 2002 Oct; 188():136-46. PubMed ID: 12445287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
    Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
    Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
    Palmowski M; Salio M; Dunbar RP; Cerundolo V
    Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.